OR52K1 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A may downregulate OR52K1 expression by preventing histone deacetylase from condensing chromatin structure, thereby restricting the transcriptional machinery's access to the gene's promoter region. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound may decrease methylation levels of the OR52K1 gene promoter, leading to a reduction in gene silencing marks and an increase in expression of the gene that could be counteracted by other cellular mechanisms, potentially resulting in overall decreased OR52K1 expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
By binding to DNA, Mithramycin A could inhibit the binding of transcription factors necessary for the initiation of OR52K1 transcription, thus decreasing its mRNA synthesis. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine (Decitabine) could lead to the demethylation of cytosine bases within the OR52K1 gene promoter, which might result in a reduction of transcriptional repression signals, indirectly leading to a decrease in OR52K1 expression as a secondary response. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
MS-275 (Entinostat) could promote the hyperacetylation of histones associated with the OR52K1 gene, which might inadvertently result in the recruitment of transcriptional repressors to the locus, thereby reducing OR52K1 expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid (Vorinostat) may lead to an open chromatin conformation around the OR52K1 gene, paradoxically allowing the binding of repressive transcription factors or co-regulators that could contribute to the downregulation of OR52K1. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
By inhibiting DNA methyltransferase, RG 108 could decrease the methylation of the OR52K1 gene, which may subsequently reduce the binding of methyl-CpG-binding domain proteins and lead to a decrease in OR52K1 transcription. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin (Sirolimus) might inhibit the mTOR pathway, which can play a role in the translation and stability of select mRNAs, potentially leading to decreased protein levels of OR52K1 without directly affecting its mRNA levels. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium Butyrate may inhibit histone deacetylation at the OR52K1 locus, leading to an unanticipated recruitment of transcriptional co-repressors that could silence OR52K1 expression. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Through activation of its nuclear receptors, Retinoic Acid may initiate a signaling cascade that culminates in the recruitment of co-repressors to the OR52K1 gene, resulting in a decrease in OR52K1 mRNA levels. | ||||||